- ADVERTISEMENT FEATURE Advertiser retains sole responsibility for the content of this article
REGISTER NOW | Date: Tuesday 30 September 2025 | 16:00 BST | 17:00 CEST | 8:00 PDT | 11:00 EDT

There is an ever-expanding need for generating soluble and active proteins to be used for downstream high-throughput screening in structural biology and drug discovery. Obtaining soluble protein constructs using cell-based approaches can be time-consuming, costly, and require tremendous resources.
While membrane proteins account for over 60 percent of drug targets, cell-based expression and extraction methods often fail due to misfolding, aggregation, and low yields, delaying structural and functional studies.
This webcast will introduce the latest update to eProtein Discovery, which enables researchers to customize cell-free expression conditions with membrane mimetics and cofactors to boost the yield of active membrane proteins that were previously difficult to produce. It will also describe how high-throughput multiplexing accelerates the identification of optimal conditions, transforming challenging targets into access to tractable proteins within days, not weeks.
Case studies will include DHODH and ZMPSTE24, two membrane-bound enzymes, and MsbA, an ABC transporter expressed in nanodiscs and validated for activity and cryo-EM analysis.
Learn:
• Best practices for optimizing membrane proteins and cofactor-dependent enzymes for functional validation
• How high-throughput multiplexing can identify optimal conditions in just 24 hours
• How eProtein Discovery accelerates difficult protein workflows, making proteins ready for drug discovery and mechanistic studies
Unable to join the live event? Watch on demand. Register now to ensure that you receive information on how to gain access after the live event.
This webcast has been produced by Nuclera, who retains sole responsibility for content. About this content.
Speaker
Toby Ost, SVP Product Development, Nuclera

Toby Ost, PhD, has 19 years experience in product development for disruptive NGS and Epigenetics-tools companies such as Solexa, Illumina and PacBio. At Nuclera, he leads the Product Development Division, developing cutting-edge protein expression, optimization and detection workflows and integrating them into the eProtein Discovery system.
Moderator
Alison Halliday, Freelance Science Writer

Alison Halliday, PhD, is a freelance science writer, focusing on life sciences, biomedicine and health stories. Following her doctorate at the University of Newcastle and postdoctoral research into human molecular genetics at University College London, she moved into science communications. With more than 25 years of experience spanning academia, industry and non-profit sectors – including a decade at Cancer Research UK – she has collaborated with Nature Custom Media since 2019.